back to conferences

Proteins Powering Nexgen Healthcare: San Francisco


29 October, 2015


South San Francisco, CA

User Group Meeting

Embassy Suites South San Francisco, South San Francisco, USA

Proteins Powering NexGen Healthcare, was a symposium focusing on the incredible potential of biomarkers to impact personalized medicine and healthcare, thanks to high fidelity detection technologies such as the ultrasensitive Simoa platform.

This unique seminar, Revolutionizing Biomarker Research and Translational Science Symposium, focused on the application of the newest tools and technologies being applied to protein biomarker research and translational science. Some of the world’s leading researchers in their fields shared presentations showcasing the application of those new tools to a wide range of therapeutic areas, including inflammation, neurology, cardiology, infectious disease, and more. There was particular emphasis on the measurement of low abundance markers using single molecule detection of the Simoa platform, and what new avenues of research those previously impossible measurements can open.

Agenda (Click on presentation title to download available PDF files).

  • Inspiring a Revolution in Personalized Healthcare by Exploiting the Power of the Protein
    Kevin Hrusovsky, Quanterix, MA USA
  • Mechanistic-based biomarkers for cardiovascular disease
    Dr. Jenny Van Eyk, Cedars Sinai Medical Center, CA USA
  • Searching for elusive serum cytokine biomarkers in asthma
    Dr. Monica Gavala, Amgen, CA USA
  • Chronic Traumatic Encephalopathy: Potential Biomarkers and Clinical Presentation
    Dr. Bob Stern, Boston University, MA USA
  • Simoa 2.0: Single molecule array Technology and Applications
    Dr. David Duffy, Quanterix, MA USA
  • A Cytokine Assay Challenge: Sensitivity and Specificity
    Jane Ruppel, Genentech, CA USA
  • Development, Validation, and Application of Ultrasensitive Simoa-based Immunoassays for Prospective Clinical Trials
    Dr. Dominic Eisinger, Myriad RBM, TX USA
  • The Role of Tau and Amyloid in Acute and Chronic Symptoms Following TBI
    Dr. Jessica Gill, National Institutes of Health, MD USA